At 6.6% CAGR, Asia Pacific Sarcopenia Treatment Market is Projected to be Worth US$ 1,164.04 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific sarcopenia treatment market was valued at US$ 696.85 million in 2022 and is expected to reach US$ 1,164.04 million by 2030, registering a CAGR of 6.6% from 2022 to 2030. Rise in malnutrition and vitamin deficiency among adults and rising awareness about sarcopenia are among the critical factors attributed to drive the Asia Pacific sarcopenia treatment market growth.

Malnutrition is one of the major risk factors for sarcopenia. According to the WHO, approximately 2.3 billion adults worldwide were undernourished as of 2021, representing nearly 30% of the global population. Among the reported risk factors, protein-energy deficiency is a frequent cause of sarcopenia. Further, vitamin D deficiency or insufficiency is positively associated with an increased risk of multiple illnesses, such as cancer, obesity, cardiovascular disease, and sarcopenia. According to the National Institutes of Health (NIH), nearly 50% of the world's population suffers from vitamin D insufficiency, and ~1 billion people are vitamin D deficient.

On the contrary, unavailability of direct interventions hampers the growth of Asia Pacific sarcopenia treatment market.

Based on treatment type, the Asia Pacific sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held 41.1% share of Asia Pacific sarcopenia treatment market in 2022, amassing US$ 286.71 million. It is projected to garner US$ 511.32 million by 2030 to register 7.5% CAGR during 2022-2030.

In terms of distribution channel, the Asia Pacific sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held 42.0% share of Asia Pacific sarcopenia treatment market in 2022, amassing US$ 292.47 million. It is anticipated to garner US$ 467.27 million by 2030 to expand at 6.0% CAGR during 2022-2030.

Based on country, the Asia Pacific sarcopenia treatment market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 31.4% share of Asia Pacific sarcopenia treatment market in 2022. It was assessed at US$ 218.95 million in 2022 and is likely to hit US$ 375.05 million by 2030, registering a CAGR of 7.0% during 2022-2030.

Key players operating in the Asia Pacific sarcopenia treatment market are Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com